Lemonade Stock Dropped February: What Investors Should Know Now
A sharp 36% February drop put Lemonade in the spotlight. This guide breaks down what happened, how the AI-driven grow...
See what results to expect from zero based budgeting and how to monitor progress with clear, actionable metrics.
19,375 articlesA sharp 36% February drop put Lemonade in the spotlight. This guide breaks down what happened, how the AI-driven grow...
Investors are asking, Has Intel's stock peaked? This in-depth guide breaks down the catalysts, risks, and valuation s...
Opendoor Technologies has shown dramatic swings from a penny-like floor to double digits—driven by hype rather than f...
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Billionaire Bill Ackman recently shifted gears, selling a former cornerstone stake to fund two AI stock bets. This mo...
This in-depth analysis breaks down Acre's Q1 2026 earnings call, pulling out practical takeaways for investors. Learn...
Investors are watching PLBY closely as plby (plby) 2026 earnings unfold. This article breaks down Q1 results, evaluat...
Biotech stocks often ride a volatile wave of news, milestones, and insider moves. In the last year, one biotechnology...
A major fund reshaped its Workiva stake in a recent SEC filing, signaling routine portfolio rebalancing rather than a...
Broad-market exposure wins again as wall street’s laziest fund edge surpasses SPY in 2026, prompting a reevaluation o...
CytomX sits at a crossroads as 2025 earnings unfold, with pipeline updates, collaboration deals, and cost discipline ...
A sharp job split shows healthcare added about 900,000 positions while other sectors shed jobs. Investors are reasses...